Cancer Investigation最新文献_第8页

Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma. 贝伐单抗联合化疗或免疫治疗治疗晚期/复发性卵巢透明细胞癌肿瘤预后的系统评价和单臂meta分析

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-05-01 Epub Date: 2026-02-23 DOI: 10.1080/07357907.2026.2618578

Yuling Gu, Yunxian Tang, Cui Zheng, Yanhua Wang

引用次数: 0

Prognostic Significance of CD4+ T Cell Transcription Factors in Tumor Microenvironment: Insights from Tumor-Infiltrating Lymphocytes in Breast Cancer. CD4+ T细胞转录因子在肿瘤微环境中的预后意义：来自乳腺癌肿瘤浸润淋巴细胞的见解。

IF 1.9 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2026-01-05 DOI: 10.1080/07357907.2025.2608139

Maryam Rezaee, Fatemeh Kheiri, Rasoul Baharlou, Nahid Nafissi

{"title":"Prognostic Significance of CD4+ T Cell Transcription Factors in Tumor Microenvironment: Insights from Tumor-Infiltrating Lymphocytes in Breast Cancer.","authors":"Maryam Rezaee, Fatemeh Kheiri, Rasoul Baharlou, Nahid Nafissi","doi":"10.1080/07357907.2025.2608139","DOIUrl":"10.1080/07357907.2025.2608139","url":null,"abstract":"The tumor microenvironment (TME) influences breast cancer progression through immune system interactions, particularly by affecting the differentiation of CD4+ T cells. This study aims to explore how the TME affects the expression of transcription factors-Foxp3, RORγt, GATA3, and T-bet-in tumor-infiltrating lymphocytes (TILs) and their implications for clinical outcomes. Forty-eight breast cancer patients were enrolled. Tumor tissues were collected, and quantitative real-time PCR was performed to assess the expression of transcription factors. Patients with positive lymphovascular invasion (LVI) and high tumor grades exhibited significantly elevated Foxp3 expression. In contrast, RORγt expression decreased in patients with advanced disease. GATA3 levels correlated positively with LVI, tumor grade and advanced tumor stages, while T-bet expression was lower in patients with positive LVI, positive lymph node and larger tumor sizes. Multivariate analysis identified RORγt as a risk factor for lymph node involvement and stage of disease, while GATA3 emerged as a protective factor. Receiver operating characteristic (ROC) analysis demonstrated GATA3's potential for late-stage detection, and RORγt as a reliable staging marker. Our findings highlight the critical role of TIL-derived transcription factors in breast cancer progression and their potential as prognostic biomarkers, emphasizing the importance of TME-mediated T cell differentiation in shaping disease outcomes.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"386-396"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHEK2 Germline Variants and Their Clinical Implications: Experience from a Turkish Hereditary Cancer Cohort. CHEK2种系变异及其临床意义：来自土耳其遗传性癌症队列的经验

IF 1.9 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2025-12-19 DOI: 10.1080/07357907.2025.2600078

Zehra Manav Yigit, Osman Semih Dikbas, Fatih Mergen, Gokay Bozkurt, Evren Gumus

{"title":"CHEK2 Germline Variants and Their Clinical Implications: Experience from a Turkish Hereditary Cancer Cohort.","authors":"Zehra Manav Yigit, Osman Semih Dikbas, Fatih Mergen, Gokay Bozkurt, Evren Gumus","doi":"10.1080/07357907.2025.2600078","DOIUrl":"10.1080/07357907.2025.2600078","url":null,"abstract":"CHEK2 is a moderate-penetrance tumor suppressor gene primarily linked to hereditary breast cancer, yet growing evidence implicates it in a wider tumor spectrum. Data from underrepresented populations, such as Türkiye, remains limited. We retrospectively analyzed 895 individuals referred for hereditary cancer evaluation between 2019 and 2025 who underwent multigene panel testing. Germline CHEK2 variants were identified using the Hereditary Cancer Solution Kit (Sophia Genetics) and classified per ACMG guidelines. Clinical, tumor, and histopathological data were reviewed. Twenty-four carriers (83.3% female) were detected: 45.8% harbored pathogenic, 41.6% likely pathogenic, and 12.5% variant of uncertain significance. Breast cancer was the most frequent (66.6%), followed by bladder cancer (8.3%), with isolated cases of ovarian, cervical, lung, papillary thyroid cancers, parathyroid adenoma, and thymoma. Missense variants predominated (75%), clustering in the FHA (66.6%) and kinase (33.4%) domains. Recurrent c.470T > C and c.1427C > T variants comprised 41.6% of all cases. Our findings highlight variant- and sex-specific patterns and underscore the relevance of population-based data in refining cancer risk assessment and management of CHEK2 carriers.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"363-371"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of Exercise Management for Frail Elderly Cancer Patients on Chemotherapy Tolerance and Complications: A Systematic Review and Meta-Analysis. 老年虚弱癌症患者运动管理对化疗耐受性和并发症的影响：系统回顾和荟萃分析

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2026-01-28 DOI: 10.1080/07357907.2026.2617207

Yudan Ni, Qing Ye, Ailing Zhang, Feng Wang, Linke Wu

{"title":"Influence of Exercise Management for Frail Elderly Cancer Patients on Chemotherapy Tolerance and Complications: A Systematic Review and Meta-Analysis.","authors":"Yudan Ni, Qing Ye, Ailing Zhang, Feng Wang, Linke Wu","doi":"10.1080/07357907.2026.2617207","DOIUrl":"10.1080/07357907.2026.2617207","url":null,"abstract":"Elderly frail cancer patients face reduced chemotherapy tolerance and higher complications. Exercise intervention shows promise, but evidence remains limited. To evaluate exercise management's impact on chemotherapy tolerance and complications in this population via systematic review and meta-analysis. Randomized controlled trials (RCTs) were retrieved from databases including PubMed and Embase from inception to July 2025. Elderly cancer patients aged ≥65 years with frailty (per standard diagnostic criteria) undergoing chemotherapy were included, comparing exercise intervention with conventional care. The Cochrane ROB 2.0 tool was used for quality assessment, and RevMan 5.4 software was employed for meta-analysis. Effect sizes were expressed as mean difference (MD), odds ratio (OR), and 95% confidence interval (CI). 18 RCTs (1655 patients) showed exercise significantly reduced complication rates (OR = 0.41, P = 0.01), severe complications (OR = 0.39, P = 0.003), improved 12-minute walking distance (MD = 45.64, P = 0.02), decreased fatigue (MD=-0.80, P = 0.002), and improved quality of life (MD=-6.11, P < 0.001). No effects on Comprehensive Complication Index or readmission rates (P > 0.05). Exercise management is a safe and effective non-pharmacological intervention that reduces chemotherapy complication risks, improves functional status, and enhances quality of life in elderly frail cancer patients. It is recommended as a supportive therapy during chemotherapy, prioritizing comprehensive exercise programs (aerobic plus resistance training), administered 3-5 times weekly for 30-60 minutes over 8-12 weeks. Individualized protocols should be developed by multidisciplinary teams (oncology, rehabilitation, and geriatrics) with dynamic tolerance assessment.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"44 4","pages":"444-458"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147520121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Tumor-Infiltrating Lymphocytes (TILs), for Patients with Triple-Negative Breast Cancer. 中性粒细胞与淋巴细胞比值及肿瘤浸润淋巴细胞（til）对三阴性乳腺癌患者预后的价值。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2026-01-12 DOI: 10.1080/07357907.2025.2612595

Marcela Soto, María Teresa Poblete, Pamela Erhenfeld, Diego Halabi

{"title":"Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Tumor-Infiltrating Lymphocytes (TILs), for Patients with Triple-Negative Breast Cancer.","authors":"Marcela Soto, María Teresa Poblete, Pamela Erhenfeld, Diego Halabi","doi":"10.1080/07357907.2025.2612595","DOIUrl":"10.1080/07357907.2025.2612595","url":null,"abstract":"During the process of carcinogenesis, inflammation originating in the tumor or its microenvironment promotes tumor growth. An elevated neutrophil-lymphocyte ratio (NLR) has been considered a biomarker associated with reduced survival in several types of cancer. A retrospective study was conducted and the results of 49 triple-negative breast cancer (TNBC) biopsies from 2012 to 2017 were reviewed. The patients were divided into two groups: those with nonbasal subtype TNBC and those with basal-like TNBC. To differentiate TNBC tumors by subtype, cytokeratin 5/6 (CK5/6) expression was assessed. The Chi-square test was used to analyze the association between the classical clinicopathological parameters and these two groups, revealing a statistically significant relationship with histological grade. For overall survival, the Kaplan-Meier method was used to analyze the data. The difference in survival was compared by univariate analysis. Patients with elevated tumor-infiltrating lymphocytes (TILs) and a NLR less than 3 had prolonged survival. NLR is a cost-effective and reliable tool that can be exploited in a wide number of scenarios during daily clinical practice.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"411-418"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Major Advances of the Year in Breast Cancer: A Point of View After the ASCO 2025 Annual Meeting. 今年乳腺癌的主要进展：ASCO 2025年年会后的观点。

IF 1.9 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2026-01-05 DOI: 10.1080/07357907.2025.2606247

Nabil Ismaili

引用次数: 0

Risk Factors and Epidemiological Trends (1990-2021) in Esophageal Cancer Across East and South Asia. 东亚和南亚食管癌的危险因素和流行病学趋势（1990-2021年）

IF 1.9 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2025-12-18 DOI: 10.1080/07357907.2025.2600079

Lovely Jain, Vikas Singh, Shalini Singla

{"title":"Risk Factors and Epidemiological Trends (1990-2021) in Esophageal Cancer Across East and South Asia.","authors":"Lovely Jain, Vikas Singh, Shalini Singla","doi":"10.1080/07357907.2025.2600079","DOIUrl":"10.1080/07357907.2025.2600079","url":null,"abstract":"Esophageal cancer remains a leading cause of cancer-related morbidity and mortality worldwide, with East and South Asia bearing a disproportionate burden. Despite global declines in age-standardized rates, these regions continue to face challenges due to sociodemographic and behavioral factors. Using Global Burden of Disease 2021 data, we analyzed trends in prevalence, incidence, mortality, and Disability-Adjusted Life Years (DALYs) from 1990 to 2021, emphasizing gender disparities and risk factor contributions. East Asia showed notable progress, with China reporting a 33.96% decrease in age-standardized incidence rate (ASIR) and a 45.78% decline in age-standardized mortality rate (ASMR). Korea also demonstrated improvements, whereas Taiwan recorded only a 4.69% reduction in ASIR but a striking 141.62% rise in ASMR. In South Asia, Bangladesh achieved a 32.74% fall in ASIR and Nepal a 19.01% decline, while Pakistan reported increases in both ASIR (+8.47%) and ASMR (+8.52%). Gender analyses revealed higher ASIR and ASMR among men, except in Pakistan where chewing tobacco drove higher female rates. Tobacco use accounted for 53.1% of the burden in South Asia and 55.2% in East Asia, dominated by smoking in East Asia and chewing tobacco in South Asia. These findings highlight the need for gender-sensitive interventions, stronger tobacco control, dietary improvement, and enhanced screening.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"372-385"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017-2025). 新发转移性腔A乳腺癌临床病理特征和预后的时间趋势：一项回顾性多中心分析（2017-2025）。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2026-01-13 DOI: 10.1080/07357907.2025.2611945

Bilgin Demir, Özgür Tanrıverdi, Taliha Güçlü, İsmail Bayrakçı, Gökhan Çolak, Sait Kitaplı, Ali Alkan, Gamze Gököz-Doğu, Sernaz Topaloglu, Sabri Barutca

{"title":"Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017-2025).","authors":"Bilgin Demir, Özgür Tanrıverdi, Taliha Güçlü, İsmail Bayrakçı, Gökhan Çolak, Sait Kitaplı, Ali Alkan, Gamze Gököz-Doğu, Sernaz Topaloglu, Sabri Barutca","doi":"10.1080/07357907.2025.2611945","DOIUrl":"10.1080/07357907.2025.2611945","url":null,"abstract":"Whether clinicopathological features of de novo Luminal A metastatic breast cancer (MBC) have evolved across recent diagnostic periods remains unclear. In this retrospective, multicenter cohort study, we evaluated temporal changes in tumor biology and outcomes among 401 women diagnosed with de novo Luminal A MBC (ER/PR-positive, HER2-negative, Ki-67 ≤ 14%) between 2017 and 2025. Patients were stratified into four consecutive diagnostic periods spanning pre-pandemic, pandemic, and post-pandemic phases. A progressive increase in tumor proliferative activity was observed, with mean Ki-67 rising from 6.38% to 13.48% (p < 0.001), accompanied by declining ER/PR expression and increasing tumor size and histologic grade. Receiver operating characteristic analysis identified 9.5% as the optimal Ki-67 cutoff for overall survival (AUC = 0.785; p < 0.001). Both Ki-67 ≥ 9.5% and later diagnostic period independently predicted poorer survival in multivariable models (HR: 2.106 and 2.412; both p < 0.001). These findings suggest a temporal shift toward a more aggressive biological phenotype, underscoring the clinical relevance of monitoring proliferation indices even within the Luminal A subtype. While causality cannot be inferred, identification of a clinically actionable Ki-67 threshold may aid risk stratification and supports future research integrating molecular profiling to clarify mechanisms underlying temporal biological change.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"397-410"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer Inducing Role of BK Polyomavirus Large T Antigen: Molecular Signaling View. BK多瘤病毒大T抗原的致癌作用：分子信号传导观点。

IF 1.9 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2025-12-26 DOI: 10.1080/07357907.2025.2599382

Maryam Rahimi Foroudi, Ramin Yaghobi, Afsoon Afshari, Jamshid Roozbeh

{"title":"Cancer Inducing Role of BK Polyomavirus Large T Antigen: Molecular Signaling View.","authors":"Maryam Rahimi Foroudi, Ramin Yaghobi, Afsoon Afshari, Jamshid Roozbeh","doi":"10.1080/07357907.2025.2599382","DOIUrl":"10.1080/07357907.2025.2599382","url":null,"abstract":"The BK polyomavirus (BKPyV), a ubiquitous human pathogen, has garnered significant attention for its potential oncogenic role, particularly in immunocompromised populations such as transplant recipients. This review synthesizes current evidence on the molecular mechanisms underlying BKPyV-associated carcinogenesis, with a focus on the viral Large T antigen (LT-Ag). LT-Ag drives oncogenic transformation primarily by inactivating tumor suppressor proteins p53 and pRb, disrupting cell cycle regulation, and inhibiting apoptosis. Additionally, it dysregulates critical signaling pathways, including Wnt/β-catenin, PI3K/Akt/mTOR, Ras/Raf/MAPK, and STAT-3, which collectively promote uncontrolled proliferation, survival, and genomic instability. A hallmark of BKPyV's oncogenicity is its capacity to integrate into the host genome, often near tumor suppressor loci, further amplifying chromosomal damage. Clinically, BKPyV has been implicated in urothelial carcinoma, renal cell carcinoma, and prostate cancer, with viral DNA and LT-Ag detected in 20-50% of tumor specimens from kidney transplant recipients (KTRs). However, epidemiological data remain contentious, as studies in immunocompetent cohorts report inconsistent associations, and viral presence in non-neoplastic tissues complicates causal interpretations. This duality BKPyV as both a latent commensal and a potential oncogenic driver underscores the need for nuanced investigation into host-virus interactions, particularly in the context of immunosuppression. Emerging diagnostic approaches, such as next-generation sequencing to map viral integration sites, and therapeutic strategies targeting LT-Ag-mediated pathways hold promise for early detection and intervention. By bridging molecular insights with clinical observations, this review advocates for longitudinal studies to clarify BKPyV's role in carcinogenesis and to refine management protocols for high-risk populations, ultimately mitigating the burden of virus-associated malignancies.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"427-443"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Cancer. 立体定向放射治疗在少转移子宫癌中的应用。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-04-01 Epub Date: 2026-01-20 DOI: 10.1080/07357907.2026.2613300

Baher Elgohari, Fatma Teke, Mohammed Mohammed, Hong Wang, Christopher J Houser, Elangovan Doraisamy, Hayeon Kim, Parul Barry, Bhanu Prasad Venkatesulu

{"title":"Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Cancer.","authors":"Baher Elgohari, Fatma Teke, Mohammed Mohammed, Hong Wang, Christopher J Houser, Elangovan Doraisamy, Hayeon Kim, Parul Barry, Bhanu Prasad Venkatesulu","doi":"10.1080/07357907.2026.2613300","DOIUrl":"10.1080/07357907.2026.2613300","url":null,"abstract":"Introduction: Limited data exist for the use of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer. We aimed to evaluate the outcomes of using SBRT for treating oligometastatic uterine cancer.Methods: This is a single-institute retrospective study evaluating the use of SBRT in patients with oligometastatic uterine cancer. Survival Endpoints were analyzed using the Kaplan-Meier method.Results: Twenty-three uterine cancer cases with 24 oligometastatic sites were identified, who received SBRT to metastatic sites between 2011 and 2022. The median follow-up period was 30 months (IQR 14-63). The median SBRT dose, fractions, and BED10 were 42 Gy (IQR: 35-45), 5 fx (IQR: 5-5), and 77 Gy (IQR: 60-86). The median time for reirradiation was 30 months (IQR 14-81). Nodal recurrences in 58% of cases were the most common site for SBRT use. The 6-month, 1-, and 2-year local control was 87%, 83%, and 77%, and locoregional control was 83%, 69%, and 64%, respectively. Acute toxicities were observed in 50% of cases with 42% of grade 1 fatigue. Late toxicities were observed in two cases (8%) of grade 2 bowel toxicity. No grade 3 or higher toxicity.Conclusion: SBRT is a safe and effective tool for the management of oligometastatic uterine cancer.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"419-426"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0